Deerfield Management Company, L.P. (Series C) Tarsus Pharmaceuticals, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.17 - $38.73 $252,555 - $388,616	10,034 New	10,034 $272,000
Q3 2023 Nov 14, 2023	BUY	$14.75 - $24.62 $11.1 Million - $18.6 Million	754,042 New	754,042 $13.4 Million
Q1 2023 May 15, 2023	SELL	$11.92 - $16.27 $2 Million - $2.74 Million	-168,182 Reduced 12.7%	1,156,032 $14.5 Million
Q2 2022 Aug 15, 2022	BUY	$11.08 - $19.08 $14.7 Million - $25.3 Million	1,324,214 New	1,324,214 $19.3 Million

Others Institutions Holding TARS

# of Institutions

170

Shares Held

43.3M

Call Options Held

484K

Put Options Held

4.1K

Rtw Investments, LP New York, NY

3.41M
Shares

$180 Million
1.79% of portfolio
Black Rock Inc. New York, NY

3.27M
Shares

$172 Million
0.0% of portfolio
Paradigm Biocapital Advisors LP New York, NY

2.44M
Shares

$129 Million
2.89% of portfolio
Tang Capital Management LLC San Diego, CA

2.25M
Shares

$119 Million
6.32% of portfolio
Morgan Stanley New York, NY

2.21M
Shares

$116 Million
0.01% of portfolio

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.4B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account